14 completed, 8 active not recruiting, 4 terminated, 1 suspended. 16 Phase 2, 14 Phase 1, 2 Phase 3, 1 Early Phase 1.
Follow Stage IIIC Cutaneous Melanoma AJCC v7: new trials by email Literature Review of Stage IIIC Cutaneous Melanoma AJCC v7 trials Research Report on Stage IIIC Cutaneous Melanoma AJCC v7
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma Anti-SEMA4D Monoclonal Antibody VX15/2503, Ipilimumab, Laboratory Biomarker Analysis - Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7 | Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 6 | 2018-06-14 | 2021-04-02 |
| Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Pembrolizumab, Talimogene Laherparepvec - Advanced Melanoma, Recurrent Melanoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 43 | 2018-06-05 | 2026-05-20 |
| Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery Glembatumumab Vedotin, Ipilimumab, Laboratory Biomarker Analysis - Advanced Malignant Solid Neoplasm, Estrogen Receptor Negative | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2018-04-20 | 2018-07-18 | |
| Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Pembrolizumab, Propranolol Hydrochloride - Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7 | Phase 1 / Phase 2 | Suspended | Roswell Park Cancer Institute | 47 | 2018-01-31 | 2026-07-15 |
| Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma Imiquimod, Biopsy, Pembrolizumab - Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7 | Early Phase 1 | Completed | Mayo Clinic | 7 | 2017-12-20 | 2026-03-19 |
| Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma Cryosurgery, Pembrolizumab, Pheresis - Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 | Phase 1 / Phase 2 | Terminated | Mayo Clinic | 7 | 2017-11-15 | 2025-06-12 |
| Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Ibrutinib, Laboratory Biomarker Analysis, Pembrolizumab - Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7 | Phase 1 | Completed | Mayo Clinic | 20 | 2017-01-31 | 2026-09-01 |
| Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma Binimetinib, Dabrafenib, Encorafenib - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 52 | 2016-12-09 | 2026-06-11 |
| Neoadjuvant and Adjuvant Checkpoint Blockade Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Cutaneous Melanoma, Mucosal Melanoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 53 | 2016-02-02 | 2024-04-05 |
| Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma Aldesleukin, Cyclophosphamide, Fludarabine Phosphate - Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7 | Phase 2 | Completed | M.D. Anderson Cancer Center | 18 | 2015-08-07 | 2025-01-15 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 140 | 2015-03-30 | 2023-10-17 |
| Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation Dabrafenib, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery - Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 58 | 2014-10-22 | 2026-08-10 |
| Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma Aldesleukin, Cyclophosphamide, Fludarabine Phosphate - Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7 | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 34 | 2014-10-15 | 2026-10-06 |
| Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Dabrafenib, Laboratory Biomarker Analysis, Onalespib - BRAF V600E Mutation Present, BRAF V600K Mutation Present | Phase 1 | Terminated | National Cancer Institute (NCI) | 22 | 2014-05-29 | 2024-10-16 |
| A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Recombinant Flt3 Ligand - Cutaneous Melanoma, Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 60 | 2014-04-09 | 2021-11-16 |
| Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Bevacizumab, Ipilimumab - Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7 | Phase 2 | Completed | National Cancer Institute (NCI) | 169 | 2014-01-24 | 2025-12-11 |
| Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer Biopsy, Biospecimen Collection, Computed Tomography - Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 27 | 2013-10-08 | 2025-01-14 |
| Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery Dabrafenib, Ipilimumab, Laboratory Biomarker Analysis - BRAF V600E Mutation Present, BRAF V600K Mutation Present | Phase 1 | Terminated | National Cancer Institute (NCI) | 15 | 2013-08-28 | 2022-03-10 |
| Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma Aldesleukin, Cyclophosphamide, Fludarabine Phosphate - Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 | Phase 2 | Completed | Fred Hutchinson Cancer Center | 11 | 2013-08-20 | 2022-11-10 |
| Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Ipilimumab, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b - Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7 | Phase 2 | Completed | National Cancer Institute (NCI) | 88 | 2013-03-25 | 2026-07-21 |
Showing 20 of 28. Sign in to see all of them.
Melanoma (28) · Neoplasm Metastasis (4) · Uveal Melanoma (4) · Carcinoma, Renal Cell (3) · Breast Neoplasms (2) · Hematologic Neoplasms (2) · Prostatic Neoplasms (2) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Glioma (1) · Hodgkin Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lung Neoplasms (1) · Lymphoma (1)
Neoplasms (28) · Neoplasms by Histologic Type (28) · Neoplasms by Site (28) · Neoplasms, Germ Cell and Embryonal (28) · Neoplasms, Nerve Tissue (28) · Neuroectodermal Tumors (28) · Nevi and Melanomas (28) · Skin Diseases (28) · Skin Neoplasms (28) · Skin and Connective Tissue Diseases (28) · Neuroendocrine Tumors (27) · Eye Diseases (4) · Eye Neoplasms (4) · Neoplasms, Glandular and Epithelial (4) · Neoplastic Processes (4)
CTLA-4 Antigen (9) · Ipilimumab (9) · Nivolumab (6) · pembrolizumab (6) · dabrafenib (5) · trametinib (5) · aldesleukin (4) · Cyclophosphamide (3) · fludarabine phosphate (3) · Biopsy (2) · Colony-Stimulating Factors (2) · Disulfides (2) · Immunoglobulin G (2) · Interferon alpha-2 (2) · Introns (2)
National Cancer Institute (NCI) (17) · M.D. Anderson Cancer Center (5) · Mayo Clinic (3) · Fred Hutchinson Cancer Center (1) · Jonsson Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1)
United States (27) · Canada (3)
Rodabe N Amaria (4) · Ahmad Tarhini (3) · Frank S Hodi (2) · Matthew S. Block, M.D., Ph.D. (2) · Antoni Ribas (1) · Antoni Ribas, MD, PhD (1) · Crystal L Mackall (1) · David H Lawson (1) · Haeseong Park (1) · Hussein A Tawbi (1) · Janice M Mehnert (1) · Jeffrey Miller (1) · Jyoti Malhotra (1) · Nina Bhardwaj (1) · Patrick A Ott (1)
PMID 36648215, PMID 25369488, PMID 25649350, PMID 26351350, PMID 29203590, PMID 29361468, PMID 30045932, PMID 31401903, PMID 32192573, PMID 35121932, PMID 35659704, PMID 36029412, PMID 37036756, PMID 37042037, PMID 38261444, PMID 39863139, PMID 39967670, PMID 40638872
U10CA021115 (5), U10CA180820 (4), U24CA196172 (3), UM1CA186716 (3), P30CA006516 (2), P30CA015704 (2), P30CA072720 (2), U01CA062490 (2), U01CA132194 (2), U01CA154967 (2), U10CA180888 (2), UM1CA186709 (2), N01CM00038 (1), N01CM00070 (1), N01CM00071 (1)